Tamibarotene: A new hope for therapeutic efficacy in hepatocellular carcinoma patients

Hepatology International

Volumn 8, Issue 1, 2014, Pages 1-3

  Fu, Junliang ^a   Zhang, Ji Yuan ^a   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TAMIBAROTENE;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84895903367     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-013-9493-5     Document Type: Editorial

References (19)

1. Colombo M, Raoul JL, Lencioni R, Galle PR, Zucman-Rossi J, Banares R, et al. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol 2013;25(6):639-651
2. Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102
3. Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30(1):381
4. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-1739.
5. Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2013;29(3):285-292
6. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497.e2-507.e2
7. Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res 2013;43(2):147-154
8. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-4300
9. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390
11. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57(4):821-829
12. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, et al. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem 1997;40(26):4222-4234
13. Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc) 2007;43(8):563-568
14. Murakami K, Matsuura T, Hasumura S, Nagamori S, Yamada Y, Saiki I. Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. Cancer Lett 2000;151(1):63-70
15. Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol 2003;15(8):1017-1025
16. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003;9(8):1033-1038
17. Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, et al. Antimyeloma effects of a novel synthetic retinoid Am 80 (Tamibarotene) through inhibition of angiogenesis. Leukemia 2005;19(6):901-909
18. Klemann C, Raveney BJ, Klemann AK, Ozawa T, von Horsten S, Shudo K, et al. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol 2009;174(6):2234-2245
19. Kanai F, Obi S, Fujiyama S, Shiina S, Tamai H, Mochizuki H, et al. An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma. Hepatol Int 2013. doi: 10.1007/s12072-013-9459-7.